Form 4: Apogee Therapeutics Director Lisa Bollinger Granted Stock Options

Apogee Therapeutics, Inc. Director Lisa Bollinger was granted stock options to purchase 14,461 shares of common stock at an exercise price of $41.66, vesting one year from the grant date.

Summary

• Lisa Bollinger, a Director of Apogee Therapeutics, Inc. (APGE), was granted stock options.
• The grant occurred on June 17, 2025.
• The options allow her to purchase 14,461 shares of Apogee Therapeutics common stock.
• The exercise price for these options is $41.66 per share.
• The options will vest on the one-year anniversary of the grant date, which is June 17, 2026.
• Vesting is contingent on her continued service to the Issuer.
• The options expire on June 17, 2035.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard compensation practice that aligns the director's interests with shareholders, generally viewed as a neutral to slightly positive event for corporate governance and long-term alignment.

Positives

• The grant of stock options to Director Lisa Bollinger aligns her interests with those of the shareholders, incentivizing long-term company performance.
• It represents a standard form of executive and director compensation, indicating ongoing commitment from key personnel.

Negatives

• No direct negatives are apparent from this routine insider transaction filing.

Risks

• The value of the stock options is subject to the future market price of Apogee Therapeutics, Inc. common stock; if the stock price does not exceed the exercise price of $41.66, the options may expire worthless.
• The vesting of the options is contingent on Lisa Bollinger's continued service to the Issuer, meaning she must remain a director for the options to vest.

Future Outlook

The stock options are set to vest on June 17, 2026, provided Lisa Bollinger continues her service to Apogee Therapeutics, Inc., allowing for potential future exercise and acquisition of common stock.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, serving as a key component of long-term incentive compensation to align leadership interests with shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to a director, with a one-year cliff vesting schedule and a ten-year expiration, is a standard compensation practice for publicly traded companies, particularly in the biotech sector.
• While specific comparable companies or projects are not detailed in this filing, this type of equity incentive is widely used by peers to attract and retain talent and align interests, such as those seen at companies like Moderna (MRNA) or BioNTech (BNTX) for their non-executive directors, though the specific grant size and exercise price would vary based on company size, stage, and individual role.

Corporate Governance

Related Party Transactions

• The grant of stock options to Lisa Bollinger, a Director of Apogee Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for increased alignment of director's interests with shareholder value creation.

Next Steps

• Vesting of the 14,461 stock options on June 17, 2026, subject to continued service.
• Potential exercise of the vested options by Lisa Bollinger at any time before the expiration date of June 17, 2035.

Key Dates

Keywords

Apogee Therapeutics, APGE, Lisa Bollinger, Stock Option, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Vesting, Common Stock